News | May 12, 2026
JB Chemicals reports muted Q4 FY26 as integration resets business
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
Expands manufacturing push & locks in major growth deals
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The private funding rose 38% amid growing international collaborations and CDMO demand
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Subscribe To Our Newsletter & Stay Updated
